KB Home
KBH
MicroStrategy
MSTR
Meritage Homes
MTH
Toll Brothers
TOL
D.R. Horton
DHI
US Stock MarketDetailed Quotes
SNY Sanofi
- 48.450
- -0.160-0.33%
Close Jan 14 16:00 ET
- 48.200
- -0.250-0.52%
Post 16:08 ET
121.47BMarket Cap26.35P/E (TTM)
48.590High47.880Low1.68MVolume48.410Open48.610Pre Close81.12MTurnover0.08%Turnover Ratio22.00P/E (Static)2.51BShares58.97052wk High1.63P/B106.86BFloat Cap43.38152wk Low2.10Dividend TTM2.21BShs Float58.970Historical High4.32%Div YieldTTM1.46%Amplitude8.844Historical Low48.261Avg Price1Lot Size
Sanofi News
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Jean-Paul Kress to join Sanofi's Board of Directors and Sanofi Initiates Phase 3 Program for PCV21 and Expands Collaboration with Sk Bioscience for Next-Generation Pneumococcal Conjugate Vaccines
6-K: Tolebrutinib Designated Breakthrough Therapy by the FDA for Non-relapsing Secondary Progressive Multiple Sclerosis and Duvakitug Positive Phase 2b Results Demonstrate Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease
6-K: Colletion of Recent Announcements
6-K: Sarclisa Recommended for EU Approval by the CHMP to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma and Dupixent sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria
6-K: Dupixent Approved in the EU as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
6-K: Dupixent Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
6-K: Sanofi and Orano Join Forces to Develop Next-Generation Radioligand Medicines and Sanofi and CD&R Partner to Fuel Opella's Ambitions in Consumer Healthcare
6-K: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants and Sanofi in discussions to sell a controlling stake in Opella
6-K: Dupixent Approved in China as the First-Ever Biologic Medicine for Patients with COPD and Dupixent Approved in the US as the First-Ever Biologic Medicine for Patients with COPD
6-K: Colletion of Recent Announcements
6-K: Colletion of Recent Announcements
6-K: Tolebrutinib Meets Primary Endpoint in HERCULES Phase 3 Study, The First and Only to Show Reduction in Disability Accumulation in Non-relapsing Secondary Progressive Multiple Sclerosis
6-K: Sarclisa Induction Treatment Demonstrated Significantly Improved Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant
6-K: Dupixent Approved in the EU as the First-Ever Targeted Therapy for Patients with COPD and NEJM Publishes ALTUVIIIO XTEND-Kids Phase 3 Data Supporting Its Potential to Transform the Treatment Landscape for Children with Severe Hemophilia A
6-K: Colletion of Recent Announcements
6-K: Colletion of Recent Announcements
6-K: Sanofi Completes Acquisition of Inhibrx, Inc
6-K: Colletion of Recent Announcements
Sanofi | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
